Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

UNCOVERED: Adc therapeutics mitsubishi tanabe ink zynlonta licensing pact in japan | History Defined

ADC Therapeutics SA (NYSE:ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta (loncastuximab tesirine-lpyl) for all hematologic and solid tumor indications in Japan.

  • Under the agreement terms, ADC Therapeutics will receive an upfront payment of $30 million and up to an additional $205 million in milestones payments. 
  • ADC Therapeutics will also receive sales-based royalties ranging in percentage from the high teens to the low twenties.
  • Mitsubishi Tanabe will conduct clinical studies of Zynlonta in Japan and will have the right to participate in any global clinical studies of the product by bearing a portion of the costs of the study.
  • In April 2021, the FDA granted accelerated approval to Zynlonta as the first and only CD19-targeted ADC as a single-agent treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. 
  • European application has been validated by the European Medicines Agency (EMA) and is under review by the EMA's Committee for Medicinal Products for Human Use (CHMP). 
  • Price Action: ADCT shares closed lower by 9.32% at $17.22 on Friday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.